These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 10638833

  • 1. Idarubicin-145-2C11-F(ab')2 promotes peripheral tolerance and reduces chronic vascular disease in mouse cardiac allografts.
    Han WR, Murray-Segal LJ, Gershenzon A, Zhang JG, Hodder AN, Pietersz GA, Mottram PL.
    Transpl Immunol; 1999 Dec; 7(4):207-13. PubMed ID: 10638833
    [Abstract] [Full Text] [Related]

  • 2. Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice.
    Mottram PL, Han WR, Murray-Segal LJ, Mandel TE, Pietersz GA, McKenzie IF.
    Transplantation; 1997 Sep 15; 64(5):684-90. PubMed ID: 9311703
    [Abstract] [Full Text] [Related]

  • 3. Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice.
    Mottram PL, Pietersz GA, Smyth MJ, Purcell LJ, Clunie GJ, McKenzie IF.
    Transplantation; 1993 Mar 15; 55(3):484-90. PubMed ID: 8456465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RN.
    J Immunol; 2000 Sep 15; 165(6):3506-18. PubMed ID: 10975872
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.
    Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R.
    Diabetes; 1992 Mar 15; 41(3):385-91. PubMed ID: 1532369
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation.
    Guo L, Fujino M, Kimura H, Funeshima N, Kitazawa Y, Harihara Y, Tezuka K, Makuuchi M, Suzuki S, Li XK.
    Transpl Immunol; 2003 Oct 01; 12(1):41-8. PubMed ID: 14551031
    [Abstract] [Full Text] [Related]

  • 19. Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.
    Goto R, You S, Zaitsu M, Chatenoud L, Wood KJ.
    Am J Transplant; 2013 Jul 01; 13(7):1655-64. PubMed ID: 23750800
    [Abstract] [Full Text] [Related]

  • 20. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
    Zhou P, Szot GL, Guo Z, Kim O, He G, Wang J, Grusby MJ, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre ML.
    J Immunol; 2000 Nov 15; 165(10):5580-7. PubMed ID: 11067913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.